Jennifer Taubert

J&J is a major player in the COVID vaccine race, thanks in large part to Taubert and her $42.2 billion pharma business. She has had to grapple with logistical complexities such as recruiting a staggering 60,000-person global trial for the vaccine candidate—one that doesn’t need to be ultra-cooled, a likely advantage for nations without robust health infrastructures.

Subscribe to The Broadsheet, our newsletter on the world’s most powerful women.